ArticleThe Lancet regional health. Western Pacific2022
Disease burden, associated mortality and economic impact of antimicrobial resistant infections in Australia.
Article in The Lancet regional health. Western Pacific, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- The Economics of Antibiotic Resistance: A Systematic Review and Meta-analysis Based on Global Research.Applied health economics and health policy · 2026Pooled it
- Metal nanoparticles as next-generation therapeutics against antimicrobial resistance: mechanisms, functionalization, and translational potential.Molecular biology reports · 2026Review
- Direct Hospitalization Costs Associated with Resistant and SusceptibleFoodborne pathogens and disease · 2026Article
- The global epidemiology of MRSA.JAC-antimicrobial resistance · 2026Review
- Societal Economic Burden of Antibiotic Resistance in Uganda: A Cost of Illness Study.PharmacoEconomics - open · 2026Article
- Rapid and high-sensitivity quantitative fluorescent immunoassay for detection ofFrontiers in microbiology · 2026Article
- No Evidence of Temperature-Driven Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2025Article
- Existing Evidence from Economic Evaluations of Antimicrobial Resistance-A Systematic Literature Review.Antibiotics (Basel, Switzerland) · 2025Review
- Central venous catheter infections: building a causal model with expert domain knowledge to inform future clinical trials.Antimicrobial resistance and infection control · 2025Article
- Dietary attribution to burden of chronic disease in Australia: a systematic analysis of the Australian Institute of health and welfare 2024 national burden of disease dataset.EClinicalMedicine · 2025Article
- Article
- Article
- Article
- Surgical Antibiotic Prophylaxis Used in A University Clinics Hospital and Antibiotic Costs: A 3-year Survey.Current therapeutic research, clinical and experimental · 2025Article
- Multidisciplinary administrative-professional-technical interventions to optimize antibiotic use and reduce resistance in a tertiary general hospital.Frontiers in pharmacology · 2025Article
- A Web-Based Dynamic Nomogram to Predict the Risk of Methicillin-Resistant Staphylococcal Infection in Patients with Pneumonia.Diagnostics (Basel, Switzerland) · 2024Article
- Responding to the AMR threat: data and information needs of stakeholders working in regional and remote Australia.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Human milk oligosaccharides regulate human macrophage polarization and activation in response toFrontiers in immunology · 2024Article
- Diversity of antimicrobial-resistant bacteria isolated from Australian chicken and pork meat.Frontiers in microbiology · 2024Article
- Molecular characteristics of CTX-M β-lactamase-producing and quinolone-resistant Escherichia coli among deer in a popular tourist spot in Japan.Access microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The growing spread of antimicrobial resistance (AMR) is accepted as a threat to humans, animals and the environment. This threat is considered to be both country specific and global, with bacteria resistant to antibiotic treatment geographically dispersed. Despite this, we have very few Australian estimates available that use national surveillance data supplemented with measures of risk, to generate reliable and actionable measures of AMR impact. These data are essential to direct policies and programs and support equitable healthcare resource utilisation. Importantly, such data can lead to implementation of programs to improved morbidity and mortality of patients with a resistant infection. Methods: Using data from a previous case-cohort study, we estimated the AMR-associated health and economic impact caused by five hospital-associated AMR pathogens ( Findings: In 2020, there were 1,031 AMR-associated deaths (95% uncertainty interval [UI] 294, 2,615) from the five resistant hospital-associated infections in Australia. The greatest odds of dying were from respiratory infections (ceftazidime-resistant Interpretation: These are the first Australian estimates of AMR-associated health and economic impact. Country-level estimates of AMR impact are needed to provide local evidence to better inform programs and health policies to reduce morbidity and mortality associated with infection. The burden in hospital is likely an underestimate of the impact of AMR due to community-associated infections where data are limited, and the AMR burden is high. This should now be the focus of future study in this area. Funding: TMW was supported by the Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE) (grant number GNT1116530) Fellowship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.